Zinc-dependent dimers observed in crystals of human endostatin

被引:121
作者
Ding, YH
Javaherian, K
Lo, KM
Chopra, R
Boehm, T
Lanciotti, J
Harris, BA
Li, Y
Shapiro, R
Hohenester, E
Timpl, R
Folkman, J
Wiley, DC
机构
[1] Childrens Hosp, Dept Surg, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Cellular Biol, Boston, MA 02115 USA
[4] Harvard Univ, Howard Hughes Med Inst, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA
[5] Childrens Hosp, Howard Hughes Med Inst, Mol Med Lab, Dept Med, Boston, MA 02115 USA
[6] Lexigen Pharmaceut Corp, Lexington, MA 02173 USA
[7] Harvard Univ, Sch Med, Ctr Biochem & Biophys Sci & Med, Dept Pathol, Boston, MA 02115 USA
[8] Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England
[9] Max Planck Inst Biochem, D-82152 Martinsried, Germany
关键词
D O I
10.1073/pnas.95.18.10443
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The crystal structure of human endostatin reveals a zinc-binding site. Atomic absorption spectroscopy indicates that zinc is a constituent of both human and murine endostatin in solution. The human endostatin zinc site is formed by three histidines at the N terminus, residues 1, 3, and, 11, and an aspartic acid at residue 76. The N-terminal loop ordered around the zinc makes a dimeric contact in human endostatin crystals. The location of the zinc site at the amino terminus, immediately adjacent to the precursor cleavage site, suggests the possibility that the zinc may be involved in activation of the antiangiogenic activity following cleavage from the inactive collagen XVIII precursor or in the cleavage process itself.
引用
收藏
页码:10443 / 10448
页数:6
相关论文
共 40 条
  • [1] [Anonymous], MOL REPLACEMENT
  • [2] A NOVEL BLOOD-COAGULATION FACTOR-IX FACTOR-X-BINDING PROTEIN WITH ANTICOAGULANT ACTIVITY FROM THE VENOM OF TRIMERESURUS-FLAVOVIRIDIS (HABU SNAKE) - ISOLATION AND CHARACTERIZATION
    ATODA, H
    MORITA, T
    [J]. JOURNAL OF BIOCHEMISTRY, 1989, 106 (05) : 808 - 813
  • [3] THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY
    BAILEY, S
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 : 760 - 763
  • [4] Crystal structure of human lithostathine, the pancreatic inhibitor of stone formation
    Bertrand, JA
    Pignol, D
    Bernard, JP
    Verdier, JM
    Dagorn, JC
    FontecillaCamps, JC
    [J]. EMBO JOURNAL, 1996, 15 (11) : 2678 - 2684
  • [5] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    Boehm, T
    Folkman, J
    Browder, T
    OReilly, MS
    [J]. NATURE, 1997, 390 (6658) : 404 - 407
  • [6] P53 and angiogenesis
    Bouck, N
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (01): : 63 - 66
  • [7] HISTIDINE-RICH GLYCOPROTEIN AND PLATELET FACTOR-4 MASK HEPARAN-SULFATE PROTEOGLYCANS RECOGNIZED BY ACIDIC AND BASIC FIBROBLAST GROWTH-FACTOR
    BROWN, KJ
    PARISH, CR
    [J]. BIOCHEMISTRY, 1994, 33 (46) : 13918 - 13927
  • [8] PURIFICATION AND CHARACTERIZATION OF A NOVEL, OLIGOMERIC, PLASMINOGEN KRINGLE 4 BINDING-PROTEIN FROM HUMAN PLASMA-TETRANECTIN
    CLEMMENSEN, I
    PETERSEN, LC
    KLUFT, C
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 156 (02): : 327 - 333
  • [9] deVries TJ, 1996, J PATHOL, V179, P260, DOI 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO
  • [10] 2-T